FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241711906> ?p ?o ?g. }

• W4241711906 abstract "Background Chronic pulmonary infection in cystic fibrosis results in progressive lung damage. Once colonisation of the lungs with Pseudomonas aeruginosa occurs, it is almost impossible to eradicate. Vaccines, aimed at reducing infection with Pseudomonas aeruginosa, have been developed. Objectives To assess the effectiveness of vaccination against Pseudomonas aeruginosa in cystic fibrosis. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register using the terms vaccines AND pseudomonas (last search 30 May 2013) and PubMed using the terms vaccin* AND cystic fibrosis (last search 30 May 2013). Selection criteria Randomised trials (published or unpublished) comparing Pseudomonas aeruginosa vaccines (oral, parenteral or intranasal) with control vaccines or no intervention in cystic fibrosis. Data collection and analysis The authors independently selected trials, assessed them and extracted data. Main results Six trials were identified. Two trials were excluded since they were not randomised and one old, small trial because it was not possible to assess whether is was randomised. The three included trials comprised 483, 476 and 37 patients, respectively. No data have been published from one of the large trials, but the company stated in a press release that the trial failed to confirm the results from an earlier study and that further clinical development was suspended. In the other large trial, relative risk for chronic infection was 0.91 (95% confidence interval 0.55 to 1.49), and in the small trial, the risk was also close to one. In the large trial, one patient was reported to have died in the observation period. In that trial, 227 adverse events (4 severe) were registered in the vaccine group and 91 (1 severe) in the control group. There was a marked rise in flagella antibody titres in the vaccine group and no change in the placebo group (P < 0.0001). Authors' conclusions Vaccines against Pseudomonas aeruginosa cannot be recommended." @default.
• W4241711906 created "2022-05-12" @default.
• W4241711906 creator A5002375158 @default.
• W4241711906 creator A5034888451 @default.
• W4241711906 date "2013-06-17" @default.
• W4241711906 modified "2023-09-29" @default.
• W4241711906 title "Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis" @default.
• W4241711906 cites W1982138525 @default.
• W4241711906 cites W1983858385 @default.
• W4241711906 cites W2044101589 @default.
• W4241711906 cites W2063850331 @default.
• W4241711906 cites W2066484939 @default.
• W4241711906 cites W2071041539 @default.
• W4241711906 cites W2077035887 @default.
• W4241711906 cites W2087993538 @default.
• W4241711906 cites W2117107524 @default.
• W4241711906 cites W2125435699 @default.
• W4241711906 cites W2155069031 @default.
• W4241711906 cites W2155893984 @default.
• W4241711906 cites W2164471608 @default.
• W4241711906 cites W4214559180 @default.
• W4241711906 cites W4247763127 @default.
• W4241711906 doi "https://doi.org/10.1002/14651858.cd001399.pub3" @default.
• W4241711906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23771707" @default.
• W4241711906 hasPublicationYear "2013" @default.
• W4241711906 type Work @default.
• W4241711906 citedByCount "11" @default.
• W4241711906 countsByYear W42417119062014 @default.
• W4241711906 countsByYear W42417119062015 @default.
• W4241711906 countsByYear W42417119062016 @default.
• W4241711906 countsByYear W42417119062021 @default.
• W4241711906 countsByYear W42417119062022 @default.
• W4241711906 countsByYear W42417119062023 @default.
• W4241711906 crossrefType "reference-entry" @default.
• W4241711906 hasAuthorship W4241711906A5002375158 @default.
• W4241711906 hasAuthorship W4241711906A5034888451 @default.
• W4241711906 hasConcept C126322002 @default.
• W4241711906 hasConcept C168563851 @default.
• W4241711906 hasConcept C2776938444 @default.
• W4241711906 hasConcept C2777637488 @default.
• W4241711906 hasConcept C44249647 @default.
• W4241711906 hasConcept C523546767 @default.
• W4241711906 hasConcept C535046627 @default.
• W4241711906 hasConcept C54355233 @default.
• W4241711906 hasConcept C71924100 @default.
• W4241711906 hasConcept C82789193 @default.
• W4241711906 hasConcept C86803240 @default.
• W4241711906 hasConcept C95190672 @default.
• W4241711906 hasConceptScore W4241711906C126322002 @default.
• W4241711906 hasConceptScore W4241711906C168563851 @default.
• W4241711906 hasConceptScore W4241711906C2776938444 @default.
• W4241711906 hasConceptScore W4241711906C2777637488 @default.
• W4241711906 hasConceptScore W4241711906C44249647 @default.
• W4241711906 hasConceptScore W4241711906C523546767 @default.
• W4241711906 hasConceptScore W4241711906C535046627 @default.
• W4241711906 hasConceptScore W4241711906C54355233 @default.
• W4241711906 hasConceptScore W4241711906C71924100 @default.
• W4241711906 hasConceptScore W4241711906C82789193 @default.
• W4241711906 hasConceptScore W4241711906C86803240 @default.
• W4241711906 hasConceptScore W4241711906C95190672 @default.
• W4241711906 hasLocation W42417119061 @default.
• W4241711906 hasLocation W42417119062 @default.
• W4241711906 hasOpenAccess W4241711906 @default.
• W4241711906 hasPrimaryLocation W42417119061 @default.
• W4241711906 hasRelatedWork W1885119863 @default.
• W4241711906 hasRelatedWork W2114346778 @default.
• W4241711906 hasRelatedWork W2335438131 @default.
• W4241711906 hasRelatedWork W2531052508 @default.
• W4241711906 hasRelatedWork W2592774827 @default.
• W4241711906 hasRelatedWork W2626084264 @default.
• W4241711906 hasRelatedWork W2762279224 @default.
• W4241711906 hasRelatedWork W2903890959 @default.
• W4241711906 hasRelatedWork W4212933565 @default.
• W4241711906 hasRelatedWork W4379197432 @default.
• W4241711906 isParatext "false" @default.
• W4241711906 isRetracted "false" @default.
• W4241711906 workType "reference-entry" @default.